Company News
HSBC Revises European Pharma Ratings, Targets Upside
HSBC cut AstraZeneca target to £165 (from £172) and lowered 2026‑27 revenue forecasts by 2.1%, keeping a buy rating.
GSK upgraded to hold with £18.60 target (up from £15); Roche and Merck KGaA cut to
